Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Adult Vaccination Ecosystem in India
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines India
    Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Spain
    Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific Antibodies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology All
    Enhancing HCP Education in Maternal Vaccination
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Saudi Arabia
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    2026 Hemophilia Fellowship – United States
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Rare Disease All
    Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Saudi Arabia
    Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing Equity
    Release Date:
    Review Process: Expert Review Panel
    Education Inflammation & Immunology Australia
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Transition of Care in VTE
    Release Date:
    Anticoagulation Education - NVAF or VTE
    Release Date:
    Review Process:
    Achievement of Treat-to-Target in Rheumatoid Arthritis
    Release Date:
    Improving Care of Chronic Pain- Physician Groups and Health Systems
    Release Date:
    Facilitation of the Diagnosis of Rheumatoid Arthritis
    Release Date:
    Pfizer and NCCN: Metastatic Breast Cancer
    Release Date:
    Pediatric Immunization Series Completion
    Release Date:
    Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic Arthritis
    Release Date:
    Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk Patients
    Release Date:
    Pfizer and American Academy of Dermatology (AAD): Patient Access to Care
    Release Date:
    Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid Arthritis
    Release Date: